Table 2.

Outcomes

	Unadjusted Molecular Test, Percent Positivity (95% Confidence Interval)	Unadjusted Relative Risk (95% Confidence Interval)	P
Analysis 1
Unvaccinated (reference)	3.1 (3.0–3.3)	Reference
At least 1 vaccination prior to screening	1.4 (1.0–1.8)	.44 (.33–.60)	<.0001
Analysis 2
Unvaccinated (reference)	3.1 (3.0–3.3)	Reference
Screening 0–10 days after first dose	2.6 (1.6–3.6)	.81 (.54–1.20)	.29
Screening >10 days after first dose, before second dose	0.9 (.4–1.4)	.28 (.16–0.49)	<.0001
Screening >0 days after second dose	0.9 (.3–1.8)	.27 (.12–0.60)	<.0001
Analysis 3
Unvaccinated (reference)	3.1 (3.0–3.3)	Reference
1 dose prior to screening	1.6 (1.1–2.1)	.49 (.36–.69)	<.0001
2 doses prior to screening	0.9 (.2–1.5)	.27 (.12–.60)	.001
Analysis 4—Pfizer only
Unvaccinated (reference)	3.1 (3.0–3.3)	Reference
Screening 0–10 days after first dose	2.7 (1.6–3.8)	.86 (.58–1.30)	.48
Screening >10 days after first dose, before second dose	0.9 (0.4–1.4)	.27 (.15–.49)	<.0001
Screening >0 days after second dose	0.9 (0.2–1.5)	.27 (.12–.60)	.001